The cathepsin K inhibitor odanacatib (ODN) is a bone formation-sparing inhibitor of osteoclastic resorption activity. This drug is currently under development for the treatment of postmenopausal osteoporosis. To support the bone safety profile of ODN, we evaluated the effects of ODN on trabecular bone hard tissue properties in the estrogen-deficient model of the ovariectomized (OVX) rhesus monkeys. Animals (n=16/group, age 11–22 years) were treated immediately af...
This site uses cookies
Essential cookies
Some cookies are essential and the website may not work correctly without them. These cookies can only be removed by changing your browser preferences.
Other cookies
We use tracking cookies and other non-essential cookies to help improve our services.
We place cookies on your device to give you the best experience of this website. If you don't change your cookie settings, we'll assume you're happy with this.